Literature DB >> 1396327

Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms.

A M Rabuazzo1, M Buscema, C Vinci, V Caltabiano, M Vetri, F Forte, R Vigneri, F Purrello.   

Abstract

Insulin secretion was studied in rat pancreatic islets after 24-h exposure to various glyburide or tolbutamide concentrations. Glucose-induced insulin release was significantly (P < 0.05) reduced in islets cultured with 0.1 microM glyburide or 100 microM tolbutamide (2098 +/- 187, 832 +/- 93, and 989 +/- 88 pg/islet.h in control, glyburide-exposed, and tolbutamide-exposed islets, respectively). When glyburide-treated islets were stimulated with glyburide or tolbutamide, insulin release was also impaired compared to that in control islets (P < 0.05). In contrast, tolbutamide-exposed islets showed an impaired response to tolbutamide, but a normal response to glyburide. To investigate the mechanism of the sulfonylurea-induced impairment of insulin secretion, we measured insulin release and Rb+ efflux (a marker of the K+ channel activity) in a perifusion system and islet Ca2+ uptake under static conditions. Insulin release in response to 16.7 mM glucose increased in control islets from 9.4 +/- 1.1 to 131 +/- 19 pg/islet.min (first phase secretion peak). Simultaneously, the fractional 86Rb+ efflux declined from 0.015 +/- 0.002% to 0.006 +/- 0.001% (change in decrement, -63.5%). Glucose-induced insulin release in glyburide- and tolbutamide-treated islets was significantly reduced (first phase peak, 22.1 +/- 5 and 39.7 +/- 8 pg/islet.min, respectively; P < 0.05), and the fractional 86Rb+ efflux decrement was -21 +/- 6% for glyburide (P < 0.005 vs. control islets) and -65 +/- 4% (not different from control) for tolbutamide. When glyburide- or tolbutamide-exposed islets were stimulated with the corresponding sulfonylurea, insulin release was impaired compared to that in control islets (P < 0.05), but, again, 86Rb+ efflux was impaired (P < 0.05) only in glyburide-exposed islets. When 45Ca2+ uptake was studied, the increase in glucose concentration from 2.8 to 16.7 mM increased calcium uptake in control islets from 1.76 +/- 0.58 to 7.27 +/- 1.36 pmol/islet.2 min (n = 4). Preexposure to 0.1 microM glyburide did not change calcium uptake at a glucose concentration of 2.8 mM (1.44 +/- 0.45 pmol/islet.2 min) but significantly reduced calcium uptake stimulated by 16.7 mM glucose (3.21 +/- 0.35 pmol/islet.2 min; n = 4; P < 0.005 compared to control islets). In contrast, preexposure to 100 microM tolbutamide did not change either basal or glucose-stimulated calcium uptake (1.44 +/- 0.45 and 6.90 +/- 0.81 pmol/islet.2 min, respectively; n = 4). These data show that in vitro chronic exposure of pancreatic islets to the sulfonylureas glyburide and tolbutamide impairs their ability to respond to a subsequent glucose or sulfonylurea stimulation.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1396327     DOI: 10.1210/endo.131.4.1396327

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets.

Authors:  K Aston-Mourney; R L Hull; S Zraika; J Udayasankar; S L Subramanian; S E Kahn
Journal:  Diabetologia       Date:  2011-04-12       Impact factor: 10.122

2.  Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide.

Authors:  N H McClenaghan; A J Ball; P R Flatt
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

3.  Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content.

Authors:  M Anello; P Gilon; J C Henquin
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

4.  Exposure to glibenclamide increases rat beta cells sensitivity to glucose.

Authors:  G Patanè; S Piro; M Anello; A M Rabuazzo; R Vigneri; F Purrello
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

5.  Different effects of glucose and glyburide on insulin secretion in rat pancreatic islets pre-exposed to interleukin-1 beta. Possible involvement of K+ and Ca2+ channels.

Authors:  M Buscema; A M Rabuazzo; C Vinci; V Caltabiano; R Vigneri; F Purrello
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

6.  Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity.

Authors:  Zhi-Quan Wang; Fu-Er Lu; San-Hua Leng; Xin-Sheng Fang; Guang Chen; Zeng-Si Wang; Li-Ping Dong; Zhong-Qing Yan
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

Review 7.  Continuous versus intermittent sulphonylurea therapy in non-insulin-dependent diabetes mellitus.

Authors:  G Grunberger
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

8.  Acute and long-term effects of nateglinide on insulin secretory pathways.

Authors:  Andrew J Ball; Peter R Flatt; Neville H McClenaghan
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

9.  Glinide, but not sulfonylurea, can evoke insulin exocytosis by repetitive stimulation: imaging analysis of insulin exocytosis by secretagogue-induced repetitive stimulations.

Authors:  Kyota Aoyagi; Mica Ohara-Imaizumi; Chiyono Nishiwaki; Yoko Nakamichi; Shinya Nagamatsu
Journal:  Exp Diabetes Res       Date:  2009-12-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.